42429-27-6

Usage

Uses

Used in Pharmaceutical Development:
L-Prolinamide hydrochloride is used as a pharmaceutical intermediate for the development of new drugs due to its unique chemical properties, which contribute to the synthesis of innovative pharmaceutical products.
Used in Research Applications:
In research, L-Prolinamide hydrochloride is used as a chemical probe to study various biological processes and mechanisms, aiding in the advancement of medical knowledge and the discovery of potential therapeutic agents.
Used in Treatment of Inflammatory Diseases:
L-Prolinamide hydrochloride is used as a potential therapeutic agent for the treatment of inflammatory diseases, leveraging its medicinal properties to modulate inflammatory responses and alleviate symptoms.
Used in Cancer Therapy:
L-Prolinamide hydrochloride is used as a potential anticancer agent, being studied for its role in the treatment of various types of cancer. Its potential role in cancer therapy is attributed to its ability to target and affect specific biological pathways involved in cancer progression.
Used in Drug Synthesis:
L-Prolinamide hydrochloride is used as a key component in the synthesis of other pharmaceutical compounds, where its chemical properties are essential for creating new and effective drugs.

InChI:InChI=1/C5H10N2O.ClH/c6-5(8)4-2-1-3-7-4;/h4,7H,1-3H2,(H2,6,8);1H

Upstream product

• 2133-40-6 L-proline methyl ester monohydrochloride 
• 3392-10-7 tert-butoxycarbonyl-L-proline N-hydroxysuccinimide ester 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 147-85-3 L-proline 
• 76409-77-3 Ac-Aib-L-Pro-NH₂ 
• 35150-07-3 (S)-tert-butyl 2-carbamoylpyrrolidine-1-carboxylate 

Downstream Products

• 83871-06-1 N-benzyloxycarbonyl-L-phenylalanyl-L-prolinamide 
• 130485-84-6 (S)-(-)-1-(2-fluoroethyl)-2-pyrrolidinecarboxamide 
• 147-85-3 L-proline 
• 82935-40-8 (S)-(-)-1-trityl-2-pyrrolidinecarboxamide 
• 155540-07-1 acryloyl-L-prolylamide 
• 73385-89-4 N-(tert-butyloxycarbonyl)-L-4-nitrophenylalanyl-L-prolinamide 
• 50654-97-2 N(α)-t-butoxycarbonyl-D-histidyl-L-prolineamide 
• 29133-55-9 N(α)-t-butoxycarbonyl-L-histidyl-L-prolineamide 
• 177657-33-9 N-MOC-L-pro-NH₂ 
• 579491-20-6 [(S)-2-((S)-2-Carbamoyl-pyrrolidin-1-yl)-1-(4-hydroxy-2,6-dimethyl-benzyl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 226249-98-5 2-carbamoyl-1-(4-chlorobenzyl)pyrrolidine 
• 1380490-70-9 (S)-1-(phenylcarbamoyl)pyrrolidine-2-carboxamide 
• 207557-35-5 (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile 
• 77400-63-6 (S)-2-[(Z)-1-((S)-2-Carbamoyl-pyrrolidine-1-carbonyl)-2-phenyl-vinylcarbamoyl]-5-oxo-pyrrolidine-1-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes

Novel piperazine-derived conformationally constrained compounds were designed, synthesized, and evaluated for in vitro Dipeptidyl peptidase-IV (DPP-IV) inhibitory activities. From a library of compounds synthesized, 1-(2-(4-(7-Chloro-4-quinolyl)piperazin-1-yl)acetyl)pyrrolidine (2g) was identified as a potential DPP-IV inhibitor exhibiting better inhibitory activity than P32/98, reference inhibitor. The in vivo studies carried out in STZ and db/db mice models indicated that the compound 2g showed moderate antihyperglycemic activity as compared to the marketed drug Sitagliptin. A two-week repeated dose study in db/db mice revealed that compound 2g significantly declined blood glucose levels with no evidence of hypoglycemia risk. Furthermore, it showed improvement in insulin resistance reversal and antidyslipidemic properties. Molecular docking studies established good binding affinity of compound 2g at the DPP-IV active site and are in favor of the observed biological data. These data collectively suggest that compound 2g is a good lead molecule for further optimization studies.

NOVEL 5-SUBSTITUTED INDOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV (DPP-IV) INHIBITORS

The present invention relates to 5-substituted indole derivatives of formula (I): having inhibitory potential of dipeptidyl peptidase IV (DPP IV) enzyme where x and R1 are defined as defined in the specification

Preparation of amino acid amides

A process for making amino acid amides, comprising reacting an amino acid, or acid salt of an amino acid, with a halogenating agent, or with a substance that reacts with carboxylic acids to form a leaving group, to form an intermediate, then reacting the intermediate with ammonia. When the amino acid or acid salt is enantiomerically pure, the amide will be a stereoisomer. An amide made by the process can be used to form levetiracetam.

Synthesis of α-amino dithioesters and endothiodipeptides

The α-amino ester hydrochlorides (1) are converted into N-protected α-amino amides (3), α-amino thioamides (4) and α-amino dithiomethylesters (5). Condensation of 5 with the alkali salts of α-amino acids gives rise to the endothiodipeptide alkali salts (7). Johann Ambrosius Barth 1996.

First successful synthesis of acryloyl-L-prolylamide derivatives

Acryloyl-L-prolylamide (1b) and its two simple derivatives, acryloyl-L- propyl-N',N'-dimethylamide (1a) and acryloyl-L-prolyl-N'-methylamide (1c), were synthesized for the first time.